{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:43:20Z","timestamp":1794411800085,"version":"4.9.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Foundation of Korea (NRF) grant funded by the Korea government","award":["2019R1A5A2027521"],"award-info":[{"award-number":["2019R1A5A2027521"]}]},{"name":"National Research Foundation of Korea (NRF) grant funded by the Korea government","award":["2020R1A5A2031185"],"award-info":[{"award-number":["2020R1A5A2031185"]}]},{"name":"Korea Ministry of Food and Drug Safety grant","award":["22213MFDS421"],"award-info":[{"award-number":["22213MFDS421"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01376-1","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:14:56Z","timestamp":1769012096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1"],"prefix":"10.1038","volume":"11","author":[{"given":"Giang Chau","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandara","family":"Loeurng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paopachapich","family":"Pa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chheng Y","family":"Seng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shee Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Haeng","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"1376_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","volume":"10","author":"A Brandenburg","year":"2024","unstructured":"Brandenburg, A., Heine, A. & Brossart, P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer 10, 749\u2013769 (2024).","journal-title":"Trends Cancer"},{"key":"1376_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth, R. E. & Jansen, K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 4, 7 (2019).","journal-title":"NPJ Vaccines"},{"key":"1376_CR3","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"1376_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1376_CR5","doi-asserted-by":"publisher","first-page":"e006628","DOI":"10.1136\/jitc-2022-006628","volume":"11","author":"R Chang","year":"2023","unstructured":"Chang, R., Gulley, J. L. & Fong, L. Vaccinating against cancer: getting to prime time. J Immunother Cancer 11, e006628 (2023).","journal-title":"J Immunother Cancer"},{"key":"1376_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/35074106","volume":"410","author":"F Hayashi","year":"2001","unstructured":"Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099\u20131103 (2001).","journal-title":"Nature"},{"key":"1376_CR7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1073\/pnas.1417945112","volume":"112","author":"M Matusiak","year":"2015","unstructured":"Matusiak, M. et al. Flagellin-induced NLRC4 phosphorylation primes the inflammasome for activation by NAIP5. Proc. Natl. Acad. Sci. USA 112, 1541\u20131546 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1376_CR8","doi-asserted-by":"publisher","first-page":"e1081328","DOI":"10.1080\/2162402X.2015.1081328","volume":"5","author":"SE Lee","year":"2016","unstructured":"Lee, S. E. et al. Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. Oncoimmunology 5, e1081328 (2016).","journal-title":"Oncoimmunology"},{"key":"1376_CR9","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1016\/j.vaccine.2013.06.054","volume":"31","author":"CT Nguyen","year":"2013","unstructured":"Nguyen, C. T. et al. Flagellin enhances tumor-specific CD8(+) T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine 31, 3879\u20133887 (2013).","journal-title":"Vaccine"},{"key":"1376_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s42003-022-04403-8","volume":"6","author":"C Gonzalez","year":"2023","unstructured":"Gonzalez, C. et al. TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy. Commun. Biol. 6, 31 (2023).","journal-title":"Commun. Biol."},{"key":"1376_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44263-2","volume":"15","author":"JS Lim","year":"2024","unstructured":"Lim, J. S. et al. Mucosal TLR5 activation controls healthspan and longevity. Nat. Commun. 15, 46 (2024).","journal-title":"Nat. Commun."},{"key":"1376_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00910-3","volume":"9","author":"W Tan","year":"2024","unstructured":"Tan, W. et al. Author correction: development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers. NPJ Vaccines 9, 121 (2024).","journal-title":"NPJ Vaccines"},{"key":"1376_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121542","volume":"286","author":"S Puth","year":"2022","unstructured":"Puth, S. et al. An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation. Biomaterials 286, 121542 (2022).","journal-title":"Biomaterials"},{"key":"1376_CR14","doi-asserted-by":"publisher","first-page":"eaak9537","DOI":"10.1126\/scitranslmed.aak9537","volume":"9","author":"JH Zheng","year":"2017","unstructured":"Zheng, J. H. et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci. Transl. Med. 9, eaak9537 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1376_CR15","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","volume":"56","author":"MJ Pittet","year":"2023","unstructured":"Pittet, M. J., Di Pilato, M., Garris, C. & Mempel, T. R. Dendritic cells as shepherds of T cell immunity in cancer. Immunity 56, 2218\u20132230 (2023).","journal-title":"Immunity"},{"key":"1376_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.trecan.2022.10.006","volume":"9","author":"M Zagorulya","year":"2023","unstructured":"Zagorulya, M. & Spranger, S. Once upon a prime: DCs shape cancer immunity. Trends Cancer 9, 172\u2013184 (2023).","journal-title":"Trends Cancer"},{"key":"1376_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo, I., Adan-Barrientos, I., Galan, M., Wculek, S. K. & Sancho, D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257\u2013277 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1376_CR18","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles, J. R., Globig, A. M., Kaech, S. M. & Wherry, E. J. CD8(+) T cells in the cancer-immunity cycle. Immunity 56, 2231\u20132253 (2023).","journal-title":"Immunity"},{"key":"1376_CR19","doi-asserted-by":"publisher","first-page":"101848","DOI":"10.1016\/j.smim.2023.101848","volume":"71","author":"C Moussion","year":"2024","unstructured":"Moussion, C. & Delamarre, L. Antigen cross-presentation by dendritic cells: a critical axis in cancer immunotherapy. Semin. Immunol. 71, 101848 (2024).","journal-title":"Semin. Immunol."},{"key":"1376_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.immuni.2022.03.006","volume":"55","author":"S Dahling","year":"2022","unstructured":"Dahling, S. et al. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. Immunity 55, 656\u2013670 e658 (2022).","journal-title":"Immunity"},{"key":"1376_CR21","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel, J. M. et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity 54, 2338\u20132353 e2336 (2021).","journal-title":"Immunity"},{"key":"1376_CR22","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/ni.2370","volume":"13","author":"JC Miller","year":"2012","unstructured":"Miller, J. C. et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13, 888\u2013899 (2012).","journal-title":"Nat. Immunol."},{"key":"1376_CR23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/0092-8674(93)90325-K","volume":"75","author":"SD Lyman","year":"1993","unstructured":"Lyman, S. D. et al. Molecular cloning of a ligand for the flt3\/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75, 1157\u20131167 (1993).","journal-title":"Cell"},{"key":"1376_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","volume":"37","author":"S Hegde","year":"2020","unstructured":"Hegde, S. et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37, 289\u2013307 e289 (2020).","journal-title":"Cancer Cell"},{"key":"1376_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19192-z","volume":"11","author":"T Oba","year":"2020","unstructured":"Oba, T. et al. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat. Commun. 11, 5415 (2020).","journal-title":"Nat. Commun."},{"key":"1376_CR26","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1021\/acsami.0c20063","volume":"13","author":"S Uthaman","year":"2021","unstructured":"Uthaman, S. et al. Tumor microenvironment-regulating immunosenescence-independent nanostimulant synergizing with near-infrared light irradiation for antitumor immunity. ACS Appl. Mater. Interfaces 13, 4844\u20134852 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"1376_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4168\/aair.2019.11.2.254","volume":"11","author":"W Tan","year":"2019","unstructured":"Tan, W. et al. A fusion protein of Derp2 allergen and flagellin suppresses experimental allergic asthma. Allergy Asthma Immunol. Res. 11, 254\u2013266 (2019).","journal-title":"Allergy Asthma Immunol. Res."},{"key":"1376_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41385-018-0104-6","volume":"12","author":"S Puth","year":"2019","unstructured":"Puth, S. et al. A built-in adjuvant-engineered mucosal vaccine against dysbiotic periodontal diseases. Mucosal Immunol. 12, 565\u2013579 (2019).","journal-title":"Mucosal Immunol."},{"key":"1376_CR29","doi-asserted-by":"publisher","first-page":"e171621","DOI":"10.1172\/JCI171621","volume":"134","author":"B Lam","year":"2024","unstructured":"Lam, B. et al. In situ vaccination via tissue-targeted cDC1 expansion enhances the immunogenicity of chemoradiation and immunotherapy. J. Clin. Invest 134, e171621 (2024).","journal-title":"J. Clin. Invest"},{"key":"1376_CR30","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1376_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose, S. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11, 1048\u20131056 (2010).","journal-title":"Lancet Oncol."},{"key":"1376_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/vaccines8030391","volume":"8","author":"L Cheng","year":"2020","unstructured":"Cheng, L., Wang, Y. & Du, J. Human papillomavirus vaccines: an updated review. Vaccines 8, 391 (2020).","journal-title":"Vaccines"},{"key":"1376_CR33","doi-asserted-by":"publisher","first-page":"200238","DOI":"10.1016\/j.tvr.2022.200238","volume":"13","author":"CA Burmeister","year":"2022","unstructured":"Burmeister, C. A. et al. Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Res 13, 200238 (2022).","journal-title":"Tumour Virus Res"},{"key":"1376_CR34","first-page":"21","volume":"56","author":"KY Lin","year":"1996","unstructured":"Lin, K. Y. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21\u201326 (1996).","journal-title":"Cancer Res."},{"key":"1376_CR35","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402\u20131410 (2016).","journal-title":"Nat. Med."},{"key":"1376_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"J Ramos da Silva","year":"2023","unstructured":"Ramos da Silva, J. et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci. Transl. Med. 15, eabn3464 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1376_CR37","doi-asserted-by":"publisher","first-page":"e008287","DOI":"10.1136\/jitc-2023-008287","volume":"12","author":"C Gomar","year":"2024","unstructured":"Gomar, C. et al. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C. J Immunother. Cancer 12, e008287 (2024).","journal-title":"J Immunother. Cancer"},{"key":"1376_CR38","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ccell.2014.11.010","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 938 (2014).","journal-title":"Cancer Cell"},{"key":"1376_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 e714 (2017).","journal-title":"Cancer Cell"},{"key":"1376_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00738-3","volume":"8","author":"K Khim","year":"2023","unstructured":"Khim, K. et al. Deglycosylation of eukaryotic-expressed flagellin restores adjuvanticity. NPJ Vaccines 8, 139 (2023).","journal-title":"NPJ Vaccines"},{"key":"1376_CR41","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1182\/blood.V96.9.3029","volume":"96","author":"K Brasel","year":"2000","unstructured":"Brasel, K., De Smedt, T., Smith, J. L. & Maliszewski, C. R. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 96, 3029\u20133039 (2000).","journal-title":"Blood"},{"key":"1376_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1189\/jlb.69.3.373","volume":"69","author":"FG Delemarre","year":"2001","unstructured":"Delemarre, F. G., Hoogeveen, P. G., De Haan-Meulman, M., Simons, P. J. & Drexhage, H. A. Homotypic cluster formation of dendritic cells, a close correlate of their state of maturation. Defects in the biobreeding diabetes-prone rat. J. Leukoc. Biol. 69, 373\u2013380 (2001).","journal-title":"J. Leukoc. Biol."},{"key":"1376_CR43","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1084\/jem.176.6.1693","volume":"176","author":"K Inaba","year":"1992","unstructured":"Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte\/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693\u20131702 (1992).","journal-title":"J. Exp. Med."},{"key":"1376_CR44","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1158\/0008-5472.CAN-21-0939","volume":"81","author":"T Oba","year":"2021","unstructured":"Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A. & Ito, F. Neoadjuvant in situ immunomodulation enhances systemic antitumor immunity against highly metastatic tumors. Cancer Res. 81, 6183\u20136195 (2021).","journal-title":"Cancer Res."},{"key":"1376_CR45","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1182\/blood-2013-12-545772","volume":"124","author":"CT Mayer","year":"2014","unstructured":"Mayer, C. T. et al. Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 124, 3081\u20133091 (2014).","journal-title":"Blood"},{"key":"1376_CR46","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00300240","volume":"24","author":"SS Cao","year":"1989","unstructured":"Cao, S. S. & Zhen, Y. S. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother. Pharm. 24, 181\u2013186 (1989).","journal-title":"Cancer Chemother. Pharm."},{"key":"1376_CR47","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1002\/eji.200526218","volume":"35","author":"MA Morris","year":"2005","unstructured":"Morris, M. A. et al. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720. Eur. J. Immunol. 35, 3570\u20133580 (2005).","journal-title":"Eur. J. Immunol."},{"key":"1376_CR48","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324\u2013336 (2016).","journal-title":"Cancer Cell"},{"key":"1376_CR49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"1376_CR50","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen, X. & Zhao, B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362, k3529 (2018).","journal-title":"BMJ"},{"key":"1376_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211 e110 (2019).","journal-title":"Immunity"},{"key":"1376_CR52","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"1376_CR53","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231\u20131243 (2019).","journal-title":"Nat. Immunol."},{"key":"1376_CR54","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","volume":"21","author":"S Upadhaya","year":"2022","unstructured":"Upadhaya, S., Neftelinov, S. T., Hodge, J. & Campbell, J. Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape. Nat. Rev. Drug Discov. 21, 482\u2013483 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1376_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","volume":"10","author":"W Xiao","year":"2025","unstructured":"Xiao, W. et al. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct. Target Ther. 10, 74 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"1376_CR56","doi-asserted-by":"publisher","first-page":"Lba9512","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512","volume":"42","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. J. Clin. Oncol. 42, Lba9512\u2013Lba9512 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1376_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30861-z","volume":"13","author":"E Mizukoshi","year":"2022","unstructured":"Mizukoshi, E. et al. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8(+) T cells. Nat. Commun. 13, 3123 (2022).","journal-title":"Nat. Commun."},{"key":"1376_CR58","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572 (2014).","journal-title":"Nature"},{"key":"1376_CR59","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168\u2013182 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1376_CR60","doi-asserted-by":"publisher","first-page":"8256","DOI":"10.1073\/pnas.0801340105","volume":"105","author":"D Shental-Bechor","year":"2008","unstructured":"Shental-Bechor, D. & Levy, Y. Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc. Natl. Acad. Sci. USA 105, 8256\u20138261 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1376_CR61","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1096\/fasebj.9.5.7896019","volume":"9","author":"G Opdenakker","year":"1995","unstructured":"Opdenakker, G., Rudd, P. M., Wormald, M., Dwek, R. A. & Van Damme, J. Cells regulate the activities of cytokines by glycosylation. FASEB J. 9, 453\u2013457 (1995).","journal-title":"FASEB J."},{"key":"1376_CR62","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1128\/IAI.74.1.694-702.2006","volume":"74","author":"SE Lee","year":"2006","unstructured":"Lee, S. E. et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect. Immun. 74, 694\u2013702 (2006).","journal-title":"Infect. Immun."},{"key":"1376_CR63","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","volume":"179","author":"CC Brown","year":"2019","unstructured":"Brown, C. C. et al. Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell 179, 846\u2013863 e824 (2019).","journal-title":"Cell"},{"key":"1376_CR64","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3389\/fimmu.2020.01513","volume":"11","author":"JA Soto","year":"2020","unstructured":"Soto, J. A. et al. The role of dendritic cells during infections caused by highly prevalent viruses. Front. Immunol. 11, 1513 (2020).","journal-title":"Front. Immunol."},{"key":"1376_CR65","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914\u2013926 (2020).","journal-title":"Nat. Immunol."},{"key":"1376_CR66","first-page":"5228","volume":"9","author":"RS Freedman","year":"2003","unstructured":"Freedman, R. S. et al. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin. Cancer Res. 9, 5228\u20135237 (2003).","journal-title":"Clin. Cancer Res."},{"key":"1376_CR67","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-020-00143-y","volume":"1","author":"N Bhardwaj","year":"2020","unstructured":"Bhardwaj, N. et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat. Cancer 1, 1204\u20131217 (2020).","journal-title":"Nat. Cancer"},{"key":"1376_CR68","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"1376_CR69","doi-asserted-by":"publisher","first-page":"e2400702","DOI":"10.1002\/advs.202400702","volume":"11","author":"X Li","year":"2024","unstructured":"Li, X., Liu, Y., Gui, J., Gan, L. & Xue, J. Cell identity and spatial distribution of PD-1\/PD-L1 blockade responders. Adv. Sci. 11, e2400702 (2024).","journal-title":"Adv. Sci."},{"key":"1376_CR70","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","volume":"23","author":"T Gebhardt","year":"2023","unstructured":"Gebhardt, T., Park, S. L. & Parish, I. A. Stem-like exhausted and memory CD8(+) T cells in cancer. Nat. Rev. Cancer 23, 780\u2013798 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"1376_CR71","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/2326-6066.CIR-21-0865","volume":"10","author":"ST Ferris","year":"2022","unstructured":"Ferris, S. T. et al. cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. Cancer Immunol. Res 10, 920\u2013931 (2022).","journal-title":"Cancer Immunol. Res"},{"key":"1376_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo7604","volume":"14","author":"AM D\u2019Alise","year":"2022","unstructured":"D\u2019Alise, A. M. et al. Adenoviral-based vaccine promotes neoantigen-specific CD8(+) T cell stemness and tumor rejection. Sci. Transl. Med. 14, eabo7604 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1376_CR73","doi-asserted-by":"publisher","first-page":"e008630","DOI":"10.1136\/jitc-2024-008799","volume":"12","author":"D Jeon","year":"2024","unstructured":"Jeon, D., Hill, E., Moseman, J. E. & McNeel, D. G. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy. J Immunother. Cancer 12, e008630 (2024).","journal-title":"J Immunother. Cancer"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01376-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:04:34Z","timestamp":1771549474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01376-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01376-1","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}